Experienced in Acute Myelomonocytic Leukemia

Dr. Brian A. Dicarlo

Oncology
CommonSpirit Health
UCLA Health Hematology Oncology
892 Aerovista Pl, Ste 240, 
San Luis Obispo, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth

Experienced in Acute Myelomonocytic Leukemia
CommonSpirit Health
UCLA Health Hematology Oncology
892 Aerovista Pl, Ste 240, 
San Luis Obispo, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Dicarlo is an Oncologist in San Luis Obispo, California. Dr. Dicarlo is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Familial Pancreatic Cancer, Paget Disease of the Breast, Lung Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Dicarlo is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
State University Of New York At Brooklyn(Medical)
Specialties
Oncology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine (Sub: Hematology)
Internal Medicine (Sub: Medical Oncology)
Fellowships
New York Presbyterian Hospital - Weill Cornell
Hospital Affiliations
Marian Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UCLA Health Hematology Oncology
892 Aerovista Pl, Ste 240, San Luis Obispo, CA 93401
Call: 805-541-8252

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


13 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 12 Less Clinical Trials

6 Total Publications

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Journal: Breast cancer research : BCR
Published: January 05, 2023
View All 6 Publications
Similar Doctors
Gorgun Akpek
Experienced in Acute Myelomonocytic Leukemia
Dr. Gorgun Akpek
Hematology | Oncology
Experienced in Acute Myelomonocytic Leukemia
Dr. Gorgun Akpek
Hematology | Oncology

Cancer Center - Dignity Health - San Luis Obispo, CA

715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
 (0.3 miles away)
805-543-5577
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Gorgun Akpek (Dr. G) is a board certified hematologist and medical oncologist who treats his patients with all types of cancer and blood related.Dr. Akpek received his MD degree from Hacettepe University, the top medical school in Turkey and did his internal medicine residency and hematology & medical oncology clinical fellowship trainings at Hacettepe University and Boston University Medical Centers. He became further specialized in Leukemia and Stem Cell/Bone Marrow Transplantation at Johns Hopkins University Department of Oncology in Baltimore, Maryland.He joined the faculty first at Johns Hopkins University and then University of Maryland Greenebaum Cancer Center as a clinical investigator and attending physician.He continued his career as a founding Director of Leukemia and Stem Cell Transplantation/Cell Therapy programs at Banner MD Anderson Cancer Center in Gilbert, Arizona and more recently he served as the Section Chief of Blood and Marrow Transplant Program (BMT) at Rush University Medical Center in Chicago.Dr. Akpek is a member of American Society of Hematology (ASH), Clinical Oncology (ASCO) and Transplantation (ASBMT). He is nationally recognized for his research by more than 100 publications and clinical work in leukemia, lymphoma, MDS, multiple myeloma and stem cell transplantation.Board Certification:Oncology, Hematology, Internal MedicineMedical School:Hacettepe University School of MedicineInternal Medicine Residency:Hacettepe University School of MedicineFellowship Training:Hacettepe University School of Medicine, Boston University Medical Center and Johns Hopkins UniversityAreas of Interest:All Cancers including: Autoimmune Cancer, Lung Cancer, Breast Cancer, Colon Cancer, Rectal Cancer,  Pancreatic Cancer, Gallbladder Cancer, Bladder Cancer, Ovarian Cancer, MelanomaAdditional Education: Master of Public Health, Johns Hopkins Bloomberg School of Public Health 2005. Awards and Recognition: Chief's Hematology and Oncology Scholar Award, Boston University 1995-1997 Jo-Ann McCaleb Amyloid Research Award 1997 Henry Christian Award, American Federation of Medical Research 2002. Dr. Akpek is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Multiple Myeloma, Myelodysplastic Syndrome (MDS), Childhood Iron Deficiency Anemia, Bone Marrow Transplant, and Splenectomy.

Keith A. Ayrons
Experienced in Acute Myelomonocytic Leukemia
Dr. Keith A. Ayrons
Oncology | Internal Medicine
Experienced in Acute Myelomonocytic Leukemia
Dr. Keith A. Ayrons
Oncology | Internal Medicine

Mission Hope Cancer Center - Medical Oncology - Arroyo Grande

850 Fair Oaks Ave, Ste 310, 
Arroyo Grande, CA 
 (9.5 miles away)
805-474-5310
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dr. Keith Ayrons grew up on Long Island, New York, and completed his bachelor’s degree in Biology at the University of Albany while volunteering at the local hospital in the Pathology department. His passion for science and early learnings in the experimental and clinical based approach inspired him to complete first, a Master’s in Microbiology from Adelphi University and then his medical degree from Wayne State University. He then completed his Internal Medicine residency, and combined fellowship in Oncology and Hematology at Stoney Brook University. In 1995, Dr. Ayrons joined a growing oncology and hematology practice in Gastonia, North Carolina, where he was a partner for 23 years. He is Board Certified in Medical Oncology, Hematology and Internal Medicine and served as past president of the Internal Medicine department. For 25 years he developed excellent patient and family relationship skills that created a loyal patient following. In 2018, Dr. Ayrons relocated to the Central Coast and is excited to be a part of the Mission Hope Cancer Center where he can continue to fulfill his passion of serving the community through providing quality care. Dr. Ayrons is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Paget Disease of the Breast.

Experienced in Acute Myelomonocytic Leukemia
Dr. Melani P. Shaum
Hematology Oncology | Hematology | Oncology
Experienced in Acute Myelomonocytic Leukemia
Dr. Melani P. Shaum
Hematology Oncology | Hematology | Oncology

Lompoc Valley Medical Center

1213 E Ocean Ave, Suite 102, 
Lompoc, CA 
 (43.2 miles away)
805-735-1155
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melani Shaum is a Hematologist Oncology specialist and a Hematologist in Lompoc, California. Dr. Shaum is rated as an Advanced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Chronic B-Cell Leukemia (CBCL), and Richter Syndrome.

VIEW MORE ACUTE MYELOMONOCYTIC LEUKEMIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dicarlo's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Dicarlo is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Familial Prostate Cancer
      Dr. Dicarlo is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    View All 19 Distinguished Conditions
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Dicarlo is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Dicarlo is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Ampullary Cancer
      Dr. Dicarlo is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Breast Cancer in Men
      Dr. Dicarlo is
      Advanced
      . Learn about Breast Cancer in Men.
      See more Breast Cancer in Men experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Dicarlo is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Dicarlo is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    View All 27 Advanced Conditions
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Myelomonocytic Leukemia
      Dr. Dicarlo is
      Experienced
      . Learn about Acute Myelomonocytic Leukemia.
      See more Acute Myelomonocytic Leukemia experts
    • Adrenal Cancer
      Dr. Dicarlo is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adult Immune Thrombocytopenia
      Dr. Dicarlo is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    View All 114 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.